Oxidative Stress Levels, JAK2V617F Mutational Status and Thrombotic Complications in Patients with Essential Thrombocythemia

被引:0
|
作者
Moisa, Cornel [1 ]
Gaman, Mihnea Alexandru [2 ]
Diaconu, Camelia Cristina [2 ,3 ]
Gaman, Amelia Maria [4 ,5 ]
机构
[1] Cty Emergency Hosp Slatina, Dept Haematol, 5 Crisan Str, Slatina 230008, Romania
[2] Carol Davila Univ Med & Pharm, 8 Eroii Sanit Blvd, Bucharest 050474, Romania
[3] Clin Emergency Hosp Bucharest, Internal Med Clin, 8 Calea Floreasca Str, Bucharest 014461, Romania
[4] Univ Med & Pharm Craiova, Dept Pathophysiol, 2 Petru Rares Str, Craiova 200349, Romania
[5] Filantropia City Hosp, Clin Haematol, 1 Filantropiei Str, Craiova 200143, Romania
来源
REVISTA DE CHIMIE | 2019年 / 70卷 / 08期
关键词
essential thrombocythemia; reactive oxygen species; total antioxidant capacity; JAK2V617F; thrombosis; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; CALRETICULIN; ACTIVATION; PLATELET; INFLAMMATION; IMPACT; MPL;
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Essential thrombocythemia (ET) is a BCR-ABL1-negative myeloproliferative neoplasm associated with thrombotic and haemorrhagic complications. Reactive oxygen species (ROS) overexpression induces a growth advantage to JAK2V617F-positive clones and, in association with a higher number of immature platelets, leukocytosis, and additional cardiovascular risk factors, leads to an increased risk for thrombotic events. We evaluated oxidative stress by measuring ROS levels and the total antioxidant capacity (TAC) in 62 ET patients and investigated the relationship between oxidative stress, JAK2V617F mutational status and the development of thrombotic events. We found higher oxidative stress levels in JAK2V617F-positive vs. JAK2V617F-negative ET cases with no significant differences between homozygous and heterozygous genotypes. Increased ROS levels and thrombotic events were more frequent in ET patients with old age at diagnosis, higher haematocrit levels or leukocytosis.
引用
收藏
页码:2822 / 2825
页数:4
相关论文
共 50 条
  • [41] DEVELOPMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA IN A PATIENT WITH JAK2V617F POSITIVE ESSENTIAL THROMBOCYTHEMIA
    Ertop, S.
    Aslaner, M.
    Gunes, G.
    Malkan, U. Y.
    Tekin, I.
    LEUKEMIA RESEARCH, 2014, 38 : S42 - S42
  • [42] Monocyte (MNC) hemostatic profile in essential thrombocythemia (ET) or polycythemia vera (PV) patients is influenced by JAK2V617F mutational load
    Vignoli, A.
    Marchetti, M.
    Russo, L.
    Panova-Noeva, M.
    Salmoiraghi, S.
    Barbui, T.
    Rambaldi, A.
    ten Cate, H.
    Falanga, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 49 - 49
  • [43] JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib
    Pieri, Lisa
    Pancrazzi, Alessandro
    Pacilli, Annalisa
    Rabuzzi, Claudia
    Rotunno, Giada
    Fanelli, Tiziana
    Guglielmelli, Paola
    Fjerza, Rajmonda
    Paoli, Chiara
    Verstovsek, Srdan
    Vannucchi, Alessandro M.
    BLOOD, 2015, 125 (21) : 3352 - 3353
  • [44] Mutational analysis of JAK2V617F in tunisian polycythemia vera patients
    Frikha, R.
    Elloumi, M.
    Kamoun, H.
    CLINICA CHIMICA ACTA, 2024, 558
  • [45] Leukocyte alkaline phosphatase expression predicts the JAK2V617F mutation status in polycythemia vera and essential thrombocythemia
    Guerini, V
    Carobbio, A.
    Salvi, A.
    Spinelli, O.
    Finazzi, G.
    Delaini, F.
    Barbui, T.
    Rambaldi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 125 - 125
  • [46] Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia
    Ji, Liying
    Qian, Mengyao
    Wu, Nana
    Wu, Jianmin
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (03) : 947 - 951
  • [47] Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia
    Medeiros, Bruno C.
    Zhang, Tong
    Lipton, Jeffrey H.
    Kamel-Reid, Suzanne
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (04) : 293 - 294
  • [48] Do we know more about essential thrombocythemia because of JAK2V617F?
    Harrison C.
    Current Hematologic Malignancy Reports, 2009, 4 (1) : 25 - 32
  • [49] Is the absence of JAK2V617F mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients
    Patriarca, Andrea
    Pompetti, Franca
    Malizia, Raniero
    Luliani, Ornella
    Di Marzio, Ilaria
    Spadano, Antonio
    Dragani, Alfredo
    BLOOD TRANSFUSION, 2010, 8 (01) : 21 - 27
  • [50] Jak2V617F Reversible Activation Shows an Essential Requirement for Jak2V617F in Myeloproliferative Neoplasms (MPNs)
    Dunbar, Andrew
    Bowman, Robert L.
    Park, Young
    Izzo, Franco
    Myers, Robert M.
    Karzai, Abdul
    Kim, Won Jun
    Maestre, Ines Fernandez
    Waarts, Michael R.
    Nazir, Abbas
    Xiao, Wenbin
    Brodsky, Max
    Farina, Mirko
    Cai, Louise
    Cai, Sheng F.
    Wang, Benjamin
    An, Wenbin
    Yang, Julie
    Mowla, Shoron
    Eisman, Shira E.
    Mishra, Tanmay
    Houston, Remie
    Guzzardi, Emily
    Benitez, Anthony R. Martinez
    Viny, Aaron D.
    Koche, Richard
    Landau, Dan A.
    Levine, Ross L.
    BLOOD, 2022, 140